Literature DB >> 3575708

Splenic implants: evaluation with radionuclide methods.

T Abu-Nema, K Nawaz, S Sadek, K Ayyash, S Tibblin, S Al-Mohannadi, H M Abdel-Dayem.   

Abstract

The viability of omental splenic implants placed in 16 patients who had undergone splenectomy was assessed with 37 technetium-99m tin colloid studies and five studies with Tc-99m-labeled denatured red blood cells (RBCs). Indications for splenectomy included trauma in eight patients, schistosomal (Bilharzial) portal hypertension in six, splenic artery aneurysm in one, and Wiskott-Aldrich syndrome in one. Studies were done within the 1st month and at various intervals up to 13 months after surgery. Implants in five of eight trauma patients were seen during the 1st month, and implants in seven of seven were seen after 6 months (one patient could not be followed up). Three of six implants in cases of portal hypertension were seen in the 1st month and four of four at 6 months (two patients were not followed up). In two of the five studies with denatured RBCs, Tc-99m tin colloid study was also done 48 hours later; in these cases denatured RBCs were more successful in showing the implants. The authors conclude that radioisotopic procedures are valuable in following up the viability of splenic implants. The "take" of splenic implants in patients with schistosomiasis is equally successful to that in trauma patients.

Entities:  

Mesh:

Year:  1987        PMID: 3575708     DOI: 10.1148/radiology.163.3.3575708

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  SPECT demonstration of splenosis.

Authors:  S Yoshida; T Suematsu; T Motohara; K Ogawa; T Koizumi; M Mizutani; M Yanase; H Fujihara; H Haranomura; Y Ishikawa
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

2.  Differential diagnosis between splenic nodules and peritoneal metastases with contrast-enhanced ultrasound based on signal-intensity characteristics during the late phase.

Authors:  M Bertolotto; E Quaia; R Zappetti; G Cester; A Turoldo
Journal:  Radiol Med       Date:  2008-10-25       Impact factor: 3.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.